[{"revision_id":8996,"revision_timestamp":"2001-11-07T19:27:00.000Z","p1":"There are many problems involved in establishing a course of treatment for HIV. Each effective drug comes with side effects, often serious and sometimes life-threatening in themselves. Common side effects include extreme nausea and diarrhea, liver damage and jaundice. Any treatment requires regular blood tests to test for continued efficacy (in terms of T-cell count and <em>viral</em> <em>load</em>), and liver function.","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8946,"revision_timestamp":"2003-09-11T18:17:00.000Z","p1":"","p2":"There are many \"dissident\" groups, e.g. the \"Scientific Group for Reappraising the HIV-AIDS Hypothesis\". Dissident scientists report that they are usually denied access to AIDS conferences and research funding. The doubts of the dissidents concern the following aspects of AIDS research: the existence of retroviruses, the validity of testing methods, epidemiological conclusions, the existence of an independent \"AIDS\" disease and the use of methods such as PCR and <em>viral</em> <em>load</em>. See http://www.virusmyth.org/.","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8945,"revision_timestamp":"2003-09-11T18:41:00.000Z","p1":"","p2":"There are many \"dissident\" groups, e.g. the \"Scientific Group for Reappraising the HIV-AIDS Hypothesis\". Dissident scientists report that they are usually not invited to attend AIDS conferences and are not granted research funding. The doubts of the dissidents concern the following aspects of AIDS research: the existence of retroviruses, the validity of testing methods, epidemiological conclusions, the existence of an independent \"AIDS\" disease and the use of methods such as PCR and <em>viral</em> <em>load</em>. See http://www.virusmyth.org/.","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8944,"revision_timestamp":"2003-09-15T07:05:00.000Z","p1":"","p2":"There are many \"dissident\" groups, e.g. the \"Scientific Group for Reappraising the HIV-AIDS Hypothesis\". Dissident scientists report that they are usually not invited to attend AIDS conferences and are not granted research funding. The doubts of the dissidents concern the following aspects of AIDS research: the existence of retroviruses, the validity of testing methods, epidemiological conclusions, the existence of an independent \"AIDS\" disease and the use of methods such as PCR and <em>viral</em> <em>load</em>. See http://www.virusmyth.org/.","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8881,"revision_timestamp":"2004-01-25T03:08:00.000Z","p1":"","p2":"","p3":"Current treatment options primarily include combinations (\"cocktails\") of 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs), and 1 protease inhibitor (pronounced \"pro-tea-ace\"). Patients on such treatments have been known to repeatedly test \"undetectable\" for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop.","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8867,"revision_timestamp":"2004-02-03T09:53:00.000Z","p1":"","p2":"","p3":"Current treatment options primarily include combinations (\"cocktails\") of two or more nucleoside analogue reverse transcriptase inhibitors (NRTIs), and protease inhibitor. Patients on such treatments have been known to repeatedly test \"undetectable\" for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment.","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8866,"revision_timestamp":"2004-02-03T10:04:00.000Z","p1":"","p2":"","p3":"Current treatment options primarily include combinations (\"cocktails\") of two or more nucleoside analogue reverse transcriptase inhibitors (NRTIs), and protease inhibitor. Patients on such treatments have been known to repeatedly test \"undetectable\" for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment. The majority of the world's infected individuals, unfortunately, do not have access to medications and treatments for HIV and AIDS.","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8861,"revision_timestamp":"2004-02-03T11:12:00.000Z","p1":"","p2":"","p3":"Current treatment options primarily include combinations (\"cocktails\") of two or more nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor. Patients on such treatments have been known to repeatedly test \"undetectable\" for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment. The majority of the world's infected individuals, unfortunately, do not have access to medications and treatments for HIV and AIDS.","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8853,"revision_timestamp":"2004-02-27T03:48:00.000Z","p1":"","p2":"","p3":"Current treatment options primarily include combinations (\"cocktails\") of two or more nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor. Patients on such treatments have been known to repeatedly test \"undetectable\" for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment. The majority of the world's infected individuals, unfortunately, do not have access to medications and treatments for HIV and AIDS.","p4":"Primary infection with HIV is called seroconversion, and may be accompanied by what is called \"seroconversion illness\" (an earlier term was \"AIDS prodrome\"). Symptoms of this include mild flu-like symptoms such as fever, aching muscles and joints, sore throat, and swollen glands (lymph nodes), other symptoms, or by no symptoms at all. Regardless of the presence or absence of initial symptoms, all newly infected individuals become asymptomatic (symptom-free). The newly infected patient is actually most infectious during the seroconversion illness as it is during this time that the HIV <em>viral</em> <em>load</em> in the body is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the HIV virus in sufficient quantities to reach an equilibrium.","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8852,"revision_timestamp":"2004-02-27T04:08:00.000Z","p1":"","p2":"","p3":"Current optimal treatment options consist of combinations (\"cocktails\") of two or more types of anti-retrovial agents such as two nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor. Patients on such treatments have been known to repeatedly test \"undetectable\" for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment. The majority of the world's infected individuals, unfortunately, do not have access to medications and treatments for HIV and AIDS.","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8822,"revision_timestamp":"2004-03-16T08:29:00.000Z","p1":"","p2":"","p3":"Current optimal treatment options consist of combinations (\"cocktails\") of two or more types of anti-retroviral agents such as two nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor. Patients on such treatments have been known to repeatedly test \"undetectable\" (that is, negative) for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment. The majority of the world's infected individuals, unfortunately, do not have access to medications and treatments for HIV and AIDS.","p4":"","p5":"Regardless of the presence or absence of initial symptoms, all newly infected individuals become asymptomatic (symptom-free). The newly infected patient is actually most infectious during the seroconversion illness as it is during this time that the HIV <em>viral</em> <em>load</em> in the body is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the HIV virus in sufficient quantities to reach an equilibrium.","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8817,"revision_timestamp":"2004-03-23T08:03:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"Regardless of the presence or absence of initial symptoms, all newly infected individuals become asymptomatic (symptom-free). The newly infected patient is actually most infectious during the seroconversion illness as it is during this time that the HIV <em>viral</em> <em>load</em> in the body is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus in sufficient quantities to reach an equilibrium.","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8754,"revision_timestamp":"2004-04-27T20:20:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"Regardless of the presence or absence of initial symptoms, all newly infected individuals become asymptomatic (symptom-free). The newly infected patient is actually most infectious during the seroconversion illness as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus in sufficient quantities to reach an equilibrium.","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8747,"revision_timestamp":"2004-05-05T08:19:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8736,"revision_timestamp":"2004-05-30T09:21:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8727,"revision_timestamp":"2004-06-23T13:44:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8584,"revision_timestamp":"2004-11-17T19:01:00.000Z","p1":"","p2":"","p3":"Current optimal treatment options consist of combinations (\"cocktails\") of two or more types of anti-retroviral agents such as two nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor or a non nucleosider reverse transcriptase inhibitor (NNRTI). Patients on such treatments have been known to repeatedly test \"undetectable\" (that is, negative) for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment. The majority of the world's infected individuals, unfortunately, do not have access to medications and treatments for HIV and AIDS.","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8526,"revision_timestamp":"2004-12-10T21:02:00.000Z","p1":"","p2":"","p3":"Current optimal treatment options consist of combinations (\"cocktails\") of two or more types of anti-retroviral agents such as two nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor or a non nucleoside reverse transcriptase inhibitor (NNRTI). Patients on such treatments have been known to repeatedly test \"undetectable\" (that is, negative) for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment. The majority of the world's infected individuals, unfortunately, do not have access to medications and treatments for HIV and AIDS.","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8521,"revision_timestamp":"2004-12-16T09:29:00.000Z","p1":"","p2":"","p3":"Current optimal treatment options consist of combinations (\"cocktails\"\") of two or more types of anti-retroviral agents such as two nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor or a non nucleoside reverse transcriptase inhibitor (NNRTI). Patients on such treatments have been known to repeatedly test \"undetectable\" (that is, negative) for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment. The majority of the world's infected individuals, unfortunately, do not have access to medications and treatments for HIV and AIDS.","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8466,"revision_timestamp":"2005-02-01T13:38:00.000Z","p1":"","p2":"","p3":"Current optimal treatment options consist of combinations of two or more types of anti-retroviral agents such as two nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor or a non nucleoside reverse transcriptase inhibitor (NNRTI). Patients on such treatments have been known to repeatedly test \"undetectable\" (that is, negative) for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment. The majority of the world's infected individuals, unfortunately, do not have access to medications and treatments for HIV and AIDS.","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8402,"revision_timestamp":"2005-03-22T17:53:00.000Z","p1":"","p2":"","p3":"Current optimal treatment options consist of combinations (\"cocktails\") of two or more types of anti-retroviral agents such as two nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor or a non nucleoside reverse transcriptase inhibitor (NNRTI). Patients on such treatments have been known to repeatedly test \"undetectable\" (that is, negative) for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase. There is also concern with such regimens that drug resistance will eventually develop. In recent years the term HAART (highly-active anti-retroviral therapy) has been commonly used to describe this form of treatment. The majority of the world's infected individuals, unfortunately, do not have access to medications and treatments for HIV and AIDS.","p4":"","p5":"Regardless of the presence or absence of initial symptoms, nearly all newly-infected individuals become asymptomatic (symptom-free). The newly infected patient is actually most infectious during the seroconversion illness as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus in sufficient quantities to reach an equilibrium.","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8389,"revision_timestamp":"2005-03-24T01:25:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"Regardless of the presence or absence of initial symptoms, nearly all newly-infected individuals become asymptomatic (symptom-free). The newly infected patient is actually most infectious during the seroconversion illness as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus.","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8358,"revision_timestamp":"2005-03-30T15:15:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"Regardless of the presence or absence of initial symptoms, nearly all newly-infected individuals become asymptomatic (symptom-free). The newly infected patient is actually most infectious during the seroconversion illness as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus in sufficient quantities to reach an equilibrium.","p6":"The current guidelines for antiretroviral therapy from the World Health Organization reflect the 2004 changes to the guidleines to defer retroviral treatment in patients with no symptoms who have a CD4 cell count above 350 and <em>viral</em> <em>load</em> under 100,000.","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8350,"revision_timestamp":"2005-03-30T23:53:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for antiretroviral therapy from the World Health Organization reflect the changes to the guidleines to defer retroviral treatment in patients with no symptoms who have a CD4 cell count above 350 and <em>viral</em> <em>load</em> under 100,000.","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8303,"revision_timestamp":"2005-04-12T14:11:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"The newly infected person may be high;y infectious as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus.","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8300,"revision_timestamp":"2005-04-13T10:00:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"The newly infected person may be highly infectious as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus.","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8261,"revision_timestamp":"2005-04-23T08:21:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for antiretroviral therapy from the World Health Organization reflect the changes to the guidelines to defer retroviral treatment in patients with no symptoms who have a CD4 cell count above 350 and <em>viral</em> <em>load</em> under 100,000.","p7":"A newly infected person may be highly infectious as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus.","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":8191,"revision_timestamp":"2005-05-16T13:07:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for antiretroviral therapy from the World Health Organization reflect the changes to the guidelines to defer retroviral treatment in patients with no AIDS defining illnesses who have a CD4 cell count above 350 and <em>viral</em> <em>load</em> under 100,000.","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7926,"revision_timestamp":"2005-06-15T18:30:00.000Z","p1":"","p2":"","p3":"Current optimal treatment options consist of combinations (\"cocktails\") of two or more types of anti-retroviral agents such as two nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor or a non nucleoside reverse transcriptase inhibitor (NNRTI). Patients on such treatments have been known to repeatedly test \"undetectable\" (that is, negative) for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase.","p4":"","p5":"","p6":"","p7":"A newly infected person may be highly infectious as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus.","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7923,"revision_timestamp":"2005-06-15T18:35:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for antiretroviral therapy from the World Health Organization recommend that antiretroviral therapy should start when a patient's CD4 count drops below 200/mm3, or an AIDS defining illness is diagnosed. The HIV/AIDS Bureau (HAB) of the U.S. Health Resources and Services Administration states that antiretroviral therapy should begin when the CD4 cell count is between 200 and 350/mm3. HAB recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7901,"revision_timestamp":"2005-06-16T14:03:00.000Z","p1":"","p2":"","p3":"Current optimal treatment options consist of combinations (\"cocktails\") of two or more types of anti-retroviral agents such as two nucleoside analogue reverse transcriptase inhibitors (NRTIs), and a protease inhibitor or a non nucleoside reverse transcriptase inhibitor (NNRTI).  Patients on such treatments have been known to repeatedly test \"undetectable\" (that is, negative) for HIV, but discontinuing therapy has thus far caused all such patients' <em>viral</em> <em>loads</em> to promptly increase.","p4":"","p5":"","p6":"The current guidelines for antiretroviral therapy from the World Health Organization recommend that antiretroviral therapy should start when a patient's CD4 count drops below 200/mm3, or an AIDS defining illness is diagnosed. The HIV/AIDS Bureau (HAB) of the U.S. Health Resources and Services Administration states that antiretroviral therapy should begin when the CD4 cell count is between 200 and 350/mm3. HAB recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment. ","p7":"A newly infected person may be highly infectious as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus.","p8":"There is currently no cure or vaccine for HIV or AIDS. Newer treatments, however, have played a part in delaying the onset of AIDS, on reducing the symptoms, and extending patients' life spans. Over the past decade the success of these anti-retroviral treatments in prolonging, and improving, the quality of life for people with AIDS has improved dramatically. Doctors prescribe these treatments because they have been shown to be effective at reducing <em>viral</em> <em>load</em> and delaying the onset of AIDS in clinical studies. Anti-retroviral treatment has been shown in studies to be effective in delaying the onset of AIDS, reducing the symptoms, and extending patients' life spans.","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7874,"revision_timestamp":"2005-06-17T16:14:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for antiretroviral therapy from the World Health Organization recommend that anti-etroviral therapy should start when a patient's CD4 count drops below 200/mm3, or an AIDS defining illness is diagnosed. The HIV/AIDS Bureau (HAB) of the U.S. Health Resources and Services Administration states that antiretroviral therapy should begin when the CD4 cell count is between 200 and 350/mm3. HAB recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p7":"A newly infected person may be highly infectious as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus.","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7873,"revision_timestamp":"2005-06-17T16:15:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for anti-retroviral therapy from the World Health Organization recommend that anti-retroviral therapy should start when a patient's CD4 count drops below 200/mm3, or an AIDS defining illness is diagnosed. The HIV/AIDS Bureau (HAB) of the U.S. Health Resources and Services Administration states that anti-retroviral therapy should begin when the CD4 cell count is between 200 and 350/mm3. HAB recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7811,"revision_timestamp":"2005-06-20T16:00:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"Chances of HIV transmission from infected male to female vaginal sex are low - under normal conditions, only about 1 in 1,000 results in infection according to the CDC estimates in the United States. Transmission of virus from females to males is only about half as likely, 1 in 10,000, though still possible. Note that these CDC estimates are averages, and actual odds of transmission of HIV via a single sexual act can be affected by other factors, such as the <em>viral</em> <em>load</em> of the infected partner or the presence of abrasions or sores on the genitals of either of the sexual partners.","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7796,"revision_timestamp":"2005-06-20T20:40:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for anti-retroviral therapy from the World Health Organization recommend that anti-retroviral therapy should start when a patient's CD4 count drops below 200/mm3, or an AIDS defining illness is diagnosed. The HIV/AIDS Bureau (HAB) of the U.S. Health Resources and Services Administration states that anti-retroviral therapy should begin when the CD4 cell count is between 200 and 350/mm3. HAB recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p7":"A newly infected person may be highly infectious as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. At this stage, the virus is still multiplying rapidly, unchecked, because the body has not yet started to produce antibodies to the virus.","p8":"","p9":"Chances of HIV transmission from infected male to female vaginal sex are low - under normal conditions, only about 10 in 10,000 results in infection according to the CDC estimates in the United States. Transmission of virus from females to males is only about half as likely, 5 in 10,000, though still possible. Note that these CDC estimates are averages, and actual odds of transmission of HIV via a single sexual act can be affected by other factors, such as the <em>viral</em> <em>load</em> of the infected partner or the presence of abrasions or sores on the genitals of either of the sexual partners.","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7614,"revision_timestamp":"2005-07-20T23:07:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"Chances of HIV transmission from infected male to female vaginal sex are low - under normal conditions, only about 10 in 10,000 results in infection according to the CDC estimates in the United States. Transmission of virus from females to males is only about half as likely, 5 in 10,000, though still possible. Note that these CDC estimates are averages, and actual odds of transmission of HIV via a single sexual act can be affected by other factors, such as the <em>viral</em> <em>load</em> of the infected partner or the presence of abrasions or sores on the genitals of either of the sexual partners.","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7613,"revision_timestamp":"2005-07-20T23:16:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for anti-retroviral therapy from the World Health Organization recommend that anti-retroviral therapy should start when a patient's CD4 count drops below 200/mm3, or an AIDS defining illness is diagnosed. The Department of Health and Human Services (DHHS), the federal agency responsible for overseeing HIV/AIDS healthcare policies in the United States, recommends that anti-retroviral therapy be started when the CD4 cell count is between 200 and 350/mm3. DHHS recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment. ","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7566,"revision_timestamp":"2005-07-22T14:21:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for anti-retroviral therapy from the World Health Organization recommend that anti-retroviral therapy should start when a patient's CD4 count drops below 200/mm3, or an AIDS defining illness is diagnosed. The Department of Health and Human Services (DHHS), the federal agency responsible for overseeing HIV/AIDS healthcare policies in the United States, recommends that anti-retroviral therapy be started when the CD4 cell count is between 200 and 350/mm3. DHHS recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment. ","p7":"","p8":"","p9":"","p10":"Some epidemiological models suggest that over half of HIV transmission occurs in the weeks following primary HIV infection before antibodies to the virus are produced. A newly infected person may be highly infectious as it is during this time that the HIV <em>viral</em> <em>load</em> in the blood plasma is highest. CDC reported a cluster of HIV infection in (31%) of 42 women, who had vaginal sex with an HIV infected man in upstate New York between February 1996 and January 1997.","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7548,"revision_timestamp":"2005-07-22T17:05:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"Chances of HIV transmission from infected male to female vaginal sex are low - under normal conditions, only about 10 in 10,000 results in infection according to the CDC estimates in the United States. Transmission of virus from females to males is only about half as likely, 5 in 10,000, though still possible. Note that these CDC estimates are averages, and actual odds of transmission of HIV via a single sexual act can be affected by other factors, such as the <em>viral</em> <em>load</em> of the infected partner or the presence of abrasions or sores on the genitals of either of the sexual partners.","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7503,"revision_timestamp":"2005-07-24T12:14:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for anti-retroviral therapy from the World Health Organization recommend that anti-retroviral therapy should start when a patient's CD4 count drops below 200/mm3, or an AIDS defining illness is diagnosed. The Department of Health and Human Services (DHHS), the federal agency responsible for overseeing HIV/AIDS healthcare policies in the United States, recommends that anti-retroviral therapy be started when the CD4 cell count is between 200 and 350/mm3. DHHS recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment. ","p7":"","p8":"","p9":"","p10":"","p11":"Individual risk of acquiring HIV and experiencing rapid disease progression is not uniform within populations\". NIH press release Some epidemiological models suggest that over half of HIV transmission occurs in the weeks following primary HIV infection before antibodies to the virus are produced. Investigators have shown that <em>viral</em> <em>loads</em> are highest in semen and blood in the weeks before antibodies develop and estimated that the likelihood of sexual transmission from a given man to a given woman would be increased about 20-fold during Primary HIV infection as compared with the same couple having the same sex act 4 months later. Most people who are infected typically suffer from days to weeks of fever with or without muscle and joint aches, fatigue, headache, sore throat, swollen glands and sometimes rash. This \"acute retroviral syndrome\" is rarely diagnosed since it is absolutely indistinguishable in most cases from infectious mononucleosis or other very common ailments.","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7501,"revision_timestamp":"2005-07-24T12:45:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"Individual risk of acquiring HIV and experiencing rapid disease progression is not uniform within populations\". NIH press release Some epidemiological models suggest that over half of HIV transmission occurs in the weeks following primary HIV infection before antibodies to the virus are produced. Investigators have shown that <em>viral</em> <em>loads</em> are highest in semen and blood in the weeks before antibodies develop and estimated that the likelihood of sexual transmission from a given man to a given woman would be increased about 20-fold during Primary HIV infection as compared with the same couple having the same sex act 4 months later. Most people who are infected typically suffer from days to weeks of fever with or without muscle and joint aches, fatigue, headache, sore throat, swollen glands and sometimes rash. This \"acute retroviral syndrome\" is rarely diagnosed because it is difficult to distinguish from other very common ailments.","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7486,"revision_timestamp":"2005-07-24T20:02:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"The current guidelines for anti-retroviral therapy from the World Health Organization recommend that anti-retroviral therapy should start when a patient's CD4 count drops below 200/mm³, or an AIDS defining illness is diagnosed. The Department of Health and Human Services (DHHS), the federal agency responsible for overseeing HIV/AIDS healthcare policies in the United States, recommends that anti-retroviral therapy be started when the CD4 cell count is between 200 and 350/mm³. DHHS recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p7":"","p8":"","p9":"","p10":"","p11":"Individual risk of acquiring HIV and experiencing rapid disease progression is not uniform within populations\". NIH press release Some epidemiological models suggest that over half of HIV transmission occurs in the weeks following primary HIV infection before antibodies to the virus are produced. Investigators have shown that <em>viral</em> <em>loads</em> are highest in semen and blood in the weeks before antibodies develop and estimated that the likelihood of sexual transmission from a given man to a given woman would be increased about 20-fold during primary HIV infection as compared with the same couple having the same sex act 4 months later. Most people who are infected typically suffer from days to weeks of fever with or without muscle and joint aches, fatigue, headache, sore throat, swollen glands and sometimes rash. This \"acute retroviral syndrome\" is rarely diagnosed because it is difficult to distinguish from other very common ailments.","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7320,"revision_timestamp":"2005-08-15T14:14:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The Department of Health and Human Services (DHHS), the federal agency responsible for overseeing HIV/AIDS healthcare policies in the United States, recommends that anti-retroviral therapy be started when the CD4 cell count is between 200 and 350/mm³. DHHS recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7312,"revision_timestamp":"2005-08-15T18:04:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"Individual risk of acquiring HIV and experiencing rapid disease progression is not uniform within populations\". NIH press release Some epidemiological models suggest that over half of HIV transmission occurs in the weeks following primary HIV infection before antibodies to the virus are produced. Investigators have shown that <em>viral</em> <em>loads</em> are highest in semen and blood in the weeks before antibodies develop and estimated that the likelihood of sexual transmission from a given man to a given woman would be increased about 20-fold during primary HIV infection as compared with the same couple having the same sex act 4 months later. Most people who are infected typically suffer from days to weeks of fever with or without muscle and joint aches, fatigue, headache, sore throat, swollen glands and sometimes rash. This \"acute retroviral syndrome\" is rarely diagnosed because it is difficult to distinguish from other very common ailments.","p12":"The Department of Health and Human Services (DHHS), the federal agency responsible for overseeing HIV/AIDS healthcare policies in the United States, recommends that anti-retroviral therapy be started when the CD4 cell count is between 200 and 350/mm³. DHHS recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p13":"There is a 15-30% risk of transmission of HIV from mother to child during during pregnancy, labour and delivery. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Transmission from mother to child after birth can also occur through breastfeeding","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7310,"revision_timestamp":"2005-08-15T18:09:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"There is a 15-30% risk of transmission of HIV from mother to child during during pregnancy, labour and delivery. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7309,"revision_timestamp":"2005-08-15T18:54:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7249,"revision_timestamp":"2005-08-26T21:04:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7205,"revision_timestamp":"2005-09-12T23:28:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"The preferred initial regimens are either efavirenz + (lamivudine or emtricitabine) + (zidovudine or tenofovir) or lopinavir boosted with ritonavir + (lamivudine or emtricitabine) plus zidovudine. The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":7056,"revision_timestamp":"2005-10-18T07:24:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"Individual risk of acquiring HIV and experiencing rapid disease progression is not uniform within populations\". NIH press release Some epidemiological models suggest that over half of HIV transmission occurs in the weeks following primary HIV infection before antibodies to the virus are produced. Investigators have shown that <em>viral</em> <em>loads</em> are highest in semen and blood in the weeks before antibodies develop and estimated that the likelihood of sexual transmission from a given man to a given woman would be increased about 20-fold during primary HIV infection as compared with the same couple having the same sex act 4 months later. Most people who are infected typically suffer from days to weeks of fever with or without muscle and joint aches, fatigue,","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6976,"revision_timestamp":"2005-11-07T20:37:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery. In developed countries the risk can of transmission of HIV from mother to child can be as low as 0-5% (note: BC, Canada, Oak Tree Clinic data) A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6974,"revision_timestamp":"2005-11-08T00:34:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"Individual risk of acquiring HIV and experiencing rapid disease progression is not uniform within populations\". NIH press release Some epidemiological models suggest that over half of HIV transmission occurs in the weeks following primary HIV infection before antibodies to the virus are produced. Investigators have shown that <em>viral</em> <em>loads</em> are highest in semen and blood in the weeks before antibodies develop and estimated that the likelihood of sexual transmission from a given man to a given woman would be increased about 20-fold during primary HIV infection as compared with the same couple having the same sex act 4 months later.","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6972,"revision_timestamp":"2005-11-08T18:21:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery. In developed countries the risk can of transmission of HIV from mother to child can be as low as 0-5% (note: BC, Canada, Oak Tree Clinic data) A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission (PMID 11873077).","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6968,"revision_timestamp":"2005-11-08T20:31:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to begin treatment.","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery. In developed countries the risk can of transmission of HIV from mother to child can be as low as 0-5% (note: BC, Canada, Oak Tree Clinic data) A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission (PMID 11873077).","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6892,"revision_timestamp":"2005-11-29T01:36:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 15-30% in Western countries and has only been seen in 2% of India based infections (Wadia et al., 2001).","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6888,"revision_timestamp":"2005-11-29T16:04:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 15-30% in Western countries and has only been seen in 1-2% of India based infections (Wadia et al., 2001).","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6794,"revision_timestamp":"2005-12-06T21:15:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia (Gray et al., 2001). These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 15-30% in Western countries (Heaton et al., 1995; White et al., 1995) and has only been seen in 1-2% of India based infections (Satischandra et al., 2000; Wadia et al., 2001).","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6793,"revision_timestamp":"2005-12-06T21:47:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery (Orendi et al., 1998). In developed countries the risk can of transmission of HIV from mother to child can be as low as 0-5%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission (Tovanabutra et al., 2002).","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6792,"revision_timestamp":"2005-12-06T22:10:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6600,"revision_timestamp":"2006-01-05T14:08:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"A test is available to measure the small amount of HIV that escapes the lymph nodes. This test, which measures HIV RNA (HIV genetic material), is referred to as the <em>viral</em> <em>load</em> test, and it has an important role in the treatment of HIV infection.","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6560,"revision_timestamp":"2006-01-11T20:55:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment.","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6555,"revision_timestamp":"2006-01-12T08:42:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery. In developed countries the risk can of transmission of HIV from mother to child can be as low as 0-5%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 15-30% in Western countries and has only been seen in 1-2% of India based infections.","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6549,"revision_timestamp":"2006-01-12T19:12:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries and has only been seen in 1-2% of India based infections.","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6537,"revision_timestamp":"2006-01-14T19:24:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment.","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery. In developed countries the risk can of transmission of HIV from mother to child can be as low as 0-5%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"","p16":"HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries and has only been seen in 1-2% of India based infections.","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6532,"revision_timestamp":"2006-01-14T21:36:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"HIV-associated dementia: HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries and has only been seen in 1-2% of India based infections.","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6516,"revision_timestamp":"2006-01-17T22:54:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment .","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6498,"revision_timestamp":"2006-01-19T22:14:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV does not depend on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6335,"revision_timestamp":"2006-02-09T00:02:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"HIV-associated dementia: HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6333,"revision_timestamp":"2006-02-09T00:13:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"HIV-associated dementia: HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6332,"revision_timestamp":"2006-02-09T00:15:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"HIV-associated dementia: HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6331,"revision_timestamp":"2006-02-09T00:18:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"HIV-associated dementia: HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries and has only been seen in 1-2% of India based infections.","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6330,"revision_timestamp":"2006-02-09T00:26:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"HIV-associated dementia: HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries and has only been seen in 1-2% of India based infections.","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6322,"revision_timestamp":"2006-02-09T16:30:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment .","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"Studies have shown that antiretroviral drugs, cesarean delivery and formula feeding reduce the chance of transmission of HIV from mother to child.","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6321,"revision_timestamp":"2006-02-09T18:15:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment .","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6320,"revision_timestamp":"2006-02-09T18:59:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6318,"revision_timestamp":"2006-02-09T19:04:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery. In developed countries the risk can of transmission of HIV from mother to child can be as low as 0-5%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6317,"revision_timestamp":"2006-02-09T19:30:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6316,"revision_timestamp":"2006-02-09T19:30:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6315,"revision_timestamp":"2006-02-09T20:28:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment.","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery. In developed countries the risk can of transmission of HIV from mother to child can be as low as 0-5%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission","p16":"HIV-associated dementia: HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries and has only been seen in 1-2% of India based infections.","p17":"","p18":"Studies have shown that antiretroviral drugs, cesarean delivery and formula feeding reduce the chance of transmission of HIV from mother to child .","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6313,"revision_timestamp":"2006-02-10T03:15:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6294,"revision_timestamp":"2006-02-12T14:16:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"HIV-associated dementia: HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia }}. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries and has only been seen in 1-2% of India based infections.","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6291,"revision_timestamp":"2006-02-12T16:31:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery. In developed countries the risk can of transmission of HIV from mother to child can be as low as 0-5%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"HIV-associated dementia: HIV-1 associated dementia (HAD) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain macrophages and microglia. These cells are actively infected with HIV and secrete neurotoxins of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>. Prevalence is between 10-20% in Western countries and has only been seen in 1-2% of India based infections.","p17":"","p18":"Studies have shown that antiretroviral drugs, cesarean delivery and formula feeding reduce the chance of transmission of HIV from mother to child.","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6263,"revision_timestamp":"2006-02-16T07:20:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment.","p13":"There is a 15-30% risk of transmission of HIV from mother to child during pregnancy, labour and delivery. In developed countries the risk can of transmission of HIV from mother to child can be as low as 0-5%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission.\"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":""},{"revision_id":6237,"revision_timestamp":"2006-02-18T22:20:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"The DHHS also recommends that doctors should assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":6151,"revision_timestamp":"2006-03-01T00:12:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not mean that you have a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5899,"revision_timestamp":"2006-03-27T23:45:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5864,"revision_timestamp":"2006-03-30T18:49:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"In developed countries where HAART is available, doctors also assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5841,"revision_timestamp":"2006-04-03T14:29:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10 fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"In developed countries where HAART is available, doctors also assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment.","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5831,"revision_timestamp":"2006-04-03T18:34:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breastfeeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5812,"revision_timestamp":"2006-04-04T00:56:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"In developed countries where HAART is available, doctors also assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment.","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5798,"revision_timestamp":"2006-04-05T00:16:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5770,"revision_timestamp":"2006-04-07T16:52:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"In developed countries where HAART is available, doctors assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment.","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5768,"revision_timestamp":"2006-04-07T19:59:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breast-feeding.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10-fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5226,"revision_timestamp":"2006-06-08T04:36:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5225,"revision_timestamp":"2006-06-08T04:37:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5224,"revision_timestamp":"2006-06-08T18:02:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5212,"revision_timestamp":"2006-06-08T21:15:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"In developed countries where HAART is available, doctors assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5211,"revision_timestamp":"2006-06-08T21:17:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"In developed countries where HAART is available, doctors assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5198,"revision_timestamp":"2006-06-10T05:24:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5196,"revision_timestamp":"2006-06-10T05:53:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":5156,"revision_timestamp":"2006-06-13T03:02:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10-15%. This risk depends on clinical factors and may vary according to the pattern and duration of breast-feeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"In developed countries where HAART is available, doctors assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment.","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":4867,"revision_timestamp":"2006-06-17T20:00:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10-fold increment of seminal HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":4646,"revision_timestamp":"2006-07-27T20:26:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"In developed countries where HAART is available, doctors assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment.","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":4494,"revision_timestamp":"2006-08-22T02:30:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10-fold increment of blood plasma HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":4400,"revision_timestamp":"2006-09-04T22:01:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10-fold increment of blood plasma HIV RNA is associated with an 81% increased rate of HIV transmission. AIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sexAIDS comes from hot sex","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":3709,"revision_timestamp":"2006-11-10T03:15:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10-fold increment of blood plasma HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":3686,"revision_timestamp":"2006-11-12T11:41:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10-fold increment of blood plasma HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":3257,"revision_timestamp":"2006-12-08T14:00:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":3211,"revision_timestamp":"2006-12-12T16:40:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":3059,"revision_timestamp":"2006-12-23T17:41:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10–15%. This risk depends on clinical factors and may vary according to the pattern and duration of breast-feeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":3041,"revision_timestamp":"2007-01-19T14:44:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":3040,"revision_timestamp":"2007-01-19T14:50:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":3025,"revision_timestamp":"2007-01-25T08:59:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"In developed countries where HAART is available, doctors assess the <em>viral</em> <em>load</em>, rapidity in CD4 decline, and patient readiness while deciding when to recommend initiating treatment.","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2903,"revision_timestamp":"2007-03-29T19:14:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in mcdonald mcdonald mcdonald mcdonald mcdonald mcdonald mcdonald mcdonald mcdonald mcdonald mcdonald mcdonald mcdonald utero during the last weeks ofmcdonald pregnancmcdonald y and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10–15%. This risk depends on clinical factors and may vary according to the pattern and duration of breast-feeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2810,"revision_timestamp":"2007-04-05T08:06:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the load, the higher the risk). Breastfeeding increases the risk of transmission by 10–15%. This risk depends on clinical factors and may vary according to the pattern and duration of breast-feeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2700,"revision_timestamp":"2007-07-16T03:36:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2524,"revision_timestamp":"2007-12-17T20:50:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the <em>viral</em> <em>load</em>, the higher the risk). Breastfeeding increases the risk of transmission by 10–15%. This risk depends on clinical factors and may vary according to the pattern and duration of breast-feeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2353,"revision_timestamp":"2008-03-10T04:16:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2321,"revision_timestamp":"2008-03-10T06:48:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the <em>viral</em> <em>load</em>, the higher the risk). Breastfeeding increases the risk of transmission by 10–15%. This risk depends on clinical factors and may vary according to the pattern and duration of breast-feeding.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2319,"revision_timestamp":"2008-03-10T19:39:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the <em>viral</em> <em>load</em>, the higher the risk). Breastfeeding increases the risk of transmission by 4.04%.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2264,"revision_timestamp":"2008-03-12T21:12:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the <em>viral</em> <em>load</em>, the higher the ris","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2263,"revision_timestamp":"2008-03-12T21:27:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the <em>viral</em> <em>load</em>, the higher the risk).","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2258,"revision_timestamp":"2008-03-12T22:20:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at bi","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2205,"revision_timestamp":"2008-03-21T20:04:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the <em>viral</em> <em>load</em>, the higher the risk). Breastfeeding increases the risk of transmission by 4.04%.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2201,"revision_timestamp":"2008-03-21T21:51:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em>","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2200,"revision_timestamp":"2008-03-21T22:15:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the viral l","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2199,"revision_timestamp":"2008-03-22T18:57:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the hi","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2196,"revision_timestamp":"2008-03-24T10:59:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the <em>viral</em> <em>load</em>, the hig","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2194,"revision_timestamp":"2008-03-25T02:29:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (t","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2192,"revision_timestamp":"2008-03-26T04:34:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> o","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2161,"revision_timestamp":"2008-04-21T16:28:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2141,"revision_timestamp":"2008-04-28T13:25:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2047,"revision_timestamp":"2008-04-29T21:08:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between the mother to the child during pregnancy, labor and delivery is 25%. However, when the mother has access to antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. A number of factors influence the risk of infection, particularly the <em>viral</em> <em>load</em> of the mother at birth (the higher the <em>viral</em> <em>load</em>, the higher the risk). Breastfeeding increases the risk of transmission by 4.04%.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. Each 10-fold increment of blood plasma HIV RNA is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":2044,"revision_timestamp":"2008-04-30T01:50:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"The transmission of the virus from the mother to the child can occur in utero during the last weeks of pregnancy and at childbirth. In the absence of treatment, the transmission rate between a mother and her child during pregnancy, labor and delivery is 25%. However, when the mother takes antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. The risk of infection is influenced by the <em>viral</em> <em>load</em> of the mother at birth, with the higher the <em>viral</em> <em>load</em>, the higher the risk. Breastfeeding also increases the risk of transmission by about 4 %.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. However, each 10-fold increase in the level of HIV in the blood is associated with an 81% increased rate of HIV transmission.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1998,"revision_timestamp":"2008-05-28T14:45:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1866,"revision_timestamp":"2009-01-02T05:02:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"However, when the mother takes antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. The risk of infection is influenced by the <em>viral</em> <em>load</em> of the mother at birth, with the higher the <em>viral</em> <em>load</em>, the higher the risk. Breastfeeding also increases the risk of transmission by about 4 %.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1668,"revision_timestamp":"2010-01-15T19:32:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1526,"revision_timestamp":"2010-09-27T18:49:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1122,"revision_timestamp":"2012-05-27T05:03:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. People who have been infected with one strain of HIV can still be infected later on in their lives by other strains.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1114,"revision_timestamp":"2012-05-27T05:47:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1095,"revision_timestamp":"2012-05-27T08:13:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. People who have been infected with one strain of HIV can still be infected later on in their lives by other strains.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1011,"revision_timestamp":"2012-06-03T02:58:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"Transmission of HIV depends on the infectiousness of the infected person and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. People who have been infected with one strain of HIV can still be infected later on in their lives by other strains.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1010,"revision_timestamp":"2012-06-03T03:14:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"However, when the mother takes antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. The risk of infection is influenced by the <em>viral</em> <em>load</em> of the mother at birth, with the higher the <em>viral</em> <em>load</em>, the higher the risk. Breastfeeding also increases the risk of transmission by about 4 %.","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1008,"revision_timestamp":"2012-06-03T03:32:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"However, when the mother takes antiretroviral therapy and gives birth by caesarean section, the rate of transmission is just 1%. The risk of infection is influenced by the <em>viral</em> <em>load</em> of the mother at birth, with the higher the <em>viral</em> <em>load</em>, the higher the risk. Breastfeeding also increases the risk of transmission by about 4 %.","p14":"","p15":"Transmission of HIV depends on the infectiousness of the infected person and the susceptibility of the uninfected partner. Infectivity seems to vary during the course of illness and is not constant between individuals. An undetectable plasma <em>viral</em> <em>load</em> does not necessarily indicate a low <em>viral</em> <em>load</em> in the seminal liquid or genital secretions. People who have been infected with one strain of HIV can still be infected later on in their lives by other strains.","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1004,"revision_timestamp":"2012-06-03T04:07:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"HIV can be transmitted from mother to child during pregnancy, during delivery, and after delivery via breastfeeding. In the absence of treatment, the transmission rate up to birth between the mother and child is around 25%. However, where combination antiretroviral drug treatment and Cesarian section are available, this risk can be reduced to as low as 1%. Postnatal mother-to-child transmission may be largely prevented by complete avoidance of breast feeding; however, this has significant associated morbidity, particularly in low-income settings (where hazards of avoiding breast-feeding may include lack of access to safe water and/or a lack of affordable formula). Exclusive breast feeding and the provision of extended antiretroviral prophylaxis to the infant are also efficacious in avoiding transmission.Cochrane Systematic Review on interventions for prevention of late postnatal mother-to-child transmission of HIV Approsimately 430,000 children were infected worldwide in 2008 (19% of all new infections), primarily by this route, and that a further 65,000 infections were averted through the provision of antiretroviral prophylaxis to HIV-positive women. The risk of infection is influenced by the <em>viral</em> <em>load</em> of the mother at birth, with the higher the <em>viral</em> <em>load</em>, the higher the risk. Breastfeeding also increases the risk of transmission by about 4 %.","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":1002,"revision_timestamp":"2012-06-03T04:14:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"HIV can be transmitted from mother to child during pregnancy, during delivery, and after delivery via breastfeeding. In the absence of treatment, the transmission rate up to birth between the mother and child is around 25%. However, where combination antiretroviral drug treatment and Cesarian section are available, this risk can be reduced to as low as 1%. Postnatal mother-to-child transmission may be largely prevented by complete avoidance of breast feeding; however, this has significant associated morbidity, particularly in low-income settings (where hazards of avoiding breast-feeding may include lack of access to safe water and/or a lack of affordable formula). Exclusive breast feeding and the provision of extended antiretroviral prophylaxis to the infant are also efficacious in avoiding transmission.Cochrane Systematic Review on interventions for prevention of late postnatal mother-to-child transmission of HIV Approsimately 430,000 children were infected worldwide in 2008 (19% of all new infections), primarily by this route, and that a further 65,000 infections were averted through the provision of antiretroviral prophylaxis to HIV-positive women. The risk of infection is influenced by the <em>viral</em> <em>load</em> of the mother at birth, with the higher the <em>viral</em> <em>load</em>, the higher the risk. Breastfeeding also increases the risk of transmission by about 4 %.","p21":"The three main transmission routes of HIV are sexual contact, exposure to infected body fluids or tissues, and from mother to child during the perinatal period. The <em>viral</em> <em>load</em> of an effected person is important both in heterosexual and vertical transmission. There is no risk of acquiring HIV if exposed to feces, nasal secretions, saliva, sputum, sweat, tears, urine, or vomit from an HIV infected person unless these are contaminated with blood. It is possible to be infected by more than one strain of HIV, which is known as HIV superinfection or coinfection.","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":989,"revision_timestamp":"2012-06-06T01:54:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"HIV can be transmitted from mother to child during pregnancy, during delivery, and after delivery via breastfeeding. This is the third most common way HIV is transmitted and in the absence of treatment, the transmission rate between the mother and child before or during birth is around 25%. However, where combination antiretroviral drug treatment and Cesarian section are available, this risk can be reduced to as low as 1%. Postnatal mother-to-child transmission may be largely prevented by complete avoidance of breast feeding; however, this has significant associated morbidity, particularly in low-income settings (where hazards of avoiding breast-feeding may include lack of access to safe water and/or a lack of affordable formula). Exclusive breast feeding and the provision of extended antiretroviral prophylaxis to the infant are also efficacious in avoiding transmission.Cochrane Systematic Review on interventions for prevention of late postnatal mother-to-child transmission of HIV Approsimately 430,000 children were infected worldwide in 2008 (19% of all new infections), primarily by this route, and that a further 65,000 infections were averted through the provision of antiretroviral prophylaxis to HIV-positive women. The risk of infection is influenced by the <em>viral</em> <em>load</em> of the mother at birth, with the higher the <em>viral</em> <em>load</em>, the higher the risk. Breastfeeding also increases the risk of transmission by about 4 %.","p21":"The three main transmission routes of HIV are sexual contact, exposure to infected body fluids or tissues, and from mother to child during the perinatal period. The <em>viral</em> <em>load</em> of an effected person is important both in heterosexual and vertical transmission. There is no risk of acquiring HIV if exposed to feces, nasal secretions, saliva, sputum, sweat, tears, urine, or vomit from an HIV infected person unless these are contaminated with blood. It is possible to be infected by more than one strain of HIV, which is known as HIV superinfection or coinfection.","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":985,"revision_timestamp":"2012-06-06T02:36:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"The three main transmission routes of HIV are sexual contact, exposure to infected body fluids or tissues, and from mother to child during the perinatal period. The <em>viral</em> <em>load</em> of an effected person is important both in heterosexual and vertical transmission. There is no risk of acquiring HIV if exposed to feces, nasal secretions, saliva, sputum, sweat, tears, urine, or vomit from an HIV infected person unless these are contaminated with blood. It is possible to be infected by more than one strain of HIV, which is known as HIV superinfection or coinfection.","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":981,"revision_timestamp":"2012-06-06T02:50:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"HIV can be transmitted from mother to child during pregnancy, during delivery, and after delivery via breastfeeding. This is the third most common way HIV is transmitted and in the absence of treatment, the transmission rate between the mother and child before or during birth is around 25%. However, where combination antiretroviral drug treatment and Cesarian section are available, this risk can be reduced to as low as 1%. Postnatal mother-to-child transmission may be largely prevented by complete avoidance of breast feeding; however, this has significant associated morbidity, particularly in low-income settings (where hazards of avoiding breast-feeding may include lack of access to safe water and/or a lack of affordable formula). Exclusive breast feeding and the provision of extended antiretroviral prophylaxis to the infant are also efficacious in avoiding transmission.Cochrane Systematic Review on interventions for prevention of late postnatal mother-to-child transmission of HIV Approsimately 430,000 children were infected worldwide in 2008 (19% of all new infections), primarily by this route, and that a further 65,000 infections were averted through the provision of antiretroviral prophylaxis to HIV-positive women. The risk of infection is influenced by the <em>viral</em> <em>load</em> of the mother at birth, with the higher the <em>viral</em> <em>load</em>, the higher the risk. Breastfeeding also increases the risk of transmission by about 4 %.","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":979,"revision_timestamp":"2012-06-06T02:59:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"HIV is transmitted by three main routes: sexual contact, exposure to infected body fluids or tissues, and from mother to child during the perinatal period. The <em>viral</em> <em>load</em> of an effected person is important both in heterosexual and vertical transmission. There is no risk of acquiring HIV if exposed to feces, nasal secretions, saliva, sputum, sweat, tears, urine, or vomit from an HIV infected person unless these are contaminated with blood. It is possible to be infected by more than one strain of HIV, which is known as HIV superinfection or coinfection.","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":977,"revision_timestamp":"2012-06-06T03:24:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"HIV is transmitted by three main routes: sexual contact, exposure to infected body fluids or tissues, and from mother to child during pregnancy, delivery, or breastfeeding (known as vertical transmission). The <em>viral</em> <em>load</em> of an effected person is important both in heterosexual and vertical transmission. There is no risk of acquiring HIV if exposed to feces, nasal secretions, saliva, sputum, sweat, tears, urine, or vomit from an HIV infected person unless these are contaminated with blood. It is possible to be infected by more than one strain of HIV, which is known as HIV superinfection or coinfection.","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":976,"revision_timestamp":"2012-06-06T04:50:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelve fold higher due to this high <em>viral</em> <em>load</em>.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":972,"revision_timestamp":"2012-06-06T05:07:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelve fold higher due to this high <em>viral</em> <em>load</em>. A persons infectivity is also greater during the late phase of the infection due to this presumed reason.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":970,"revision_timestamp":"2012-06-06T05:17:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelve fold higher due to this high <em>viral</em> <em>load</em>. Where the person is in the late stages of infection rates of transmission are approximately eight fold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":964,"revision_timestamp":"2012-06-06T05:46:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"HIV can be transmitted from mother to child during pregnancy, during delivery, and after delivery via breastfeeding. This is the third most common way HIV is transmitted and in the absence of treatment, the transmission rate between the mother and child before or during birth is around 25%. However, where combination antiretroviral drug treatment and Cesarian section are available, this risk can be reduced to as low as 1%. Postnatal mother-to-child transmission may be largely prevented by complete avoidance of breast feeding; however, this has significant associated morbidity, particularly in low-income settings (where hazards of avoiding breast-feeding may include lack of access to safe water and/or a lack of affordable formula). Exclusive breast feeding and the provision of extended antiretroviral prophylaxis to the infant are also efficacious in avoiding transmission.Cochrane Systematic Review on interventions for prevention of late postnatal mother-to-child transmission of HIV Approsimately 430,000 children were infected worldwide in 2008 (19% of all new infections), primarily by this route, and that a further 65,000 infections were averted through the provision of antiretroviral prophylaxis to HIV-positive women. The risk of infection is influenced by the <em>viral</em> <em>load</em> of the mother at birth, with the higher the <em>viral</em> <em>load</em>, the higher the risk. Breastfeeding also increases the risk of transmission by about 4 %. If blood contaminates food during pre-chewing it may pose a risk of transmission.","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":911,"revision_timestamp":"2012-06-07T02:42:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"AIDS dementia complex (ADC) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of HIV infected brain macrophages and microglia. These cells are productively infected by HIV and secrete neurotoxins of both host and viral origin. Specific neurological impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and are associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>.","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelve fold higher due to this high <em>viral</em> <em>load</em>. Where the person is in the late stages of infection rates of transmission are approximately eight fold greater.","p23":"Infection with HIV-1 is associated with a progressive decrease of the CD4+ T cell count and an increase in <em>viral</em> <em>load</em>, the level of HIV in the blood. The stage of infection can be determined by measuring the patient's CD4+ T cell count and <em>viral</em> <em>load</em>.","p24":"A small percentage of HIV-1 infected individuals retain high levels of CD4+ T-cells without antiretroviral therapy. However, most have detectable <em>viral</em> <em>load</em> and will eventually progress to AIDS without treatment, albeit more slowly than others. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and also have low or clinically undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as elite controllers or elite suppressors (ES).","p25":"","p26":"","p27":""},{"revision_id":906,"revision_timestamp":"2012-06-07T02:58:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"AIDS dementia complex (ADC) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of HIV infected brain macrophages and microglia. These cells are productively infected by HIV and secrete neurotoxins of both host and viral origin. Specific neurological impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and are associated with low CD4+ T cell levels and high plasma <em>viral</em> <em>loads</em>.","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelve fold higher due to this high <em>viral</em> <em>load</em>. Where the person is in the late stages of infection rates of transmission are approximately eight fold greater.","p23":"Infection with HIV-1 is associated with a progressive decrease of the CD4+ T cell count and an increase in <em>viral</em> <em>load</em>, the level of HIV in the blood. The stage of infection can be determined by measuring the persons's CD4+ T cell count and <em>viral</em> <em>load</em>.","p24":"A small percentage of HIV-1 infected individuals retain high levels of CD4+ T-cells without antiretroviral therapy. However, most have detectable <em>viral</em> <em>load</em> and will eventually progress to AIDS without treatment, albeit more slowly than others. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and also have low or clinically undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as elite controllers or elite suppressors (ES).","p25":"","p26":"","p27":""},{"revision_id":905,"revision_timestamp":"2012-06-07T03:05:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelve fold higher due to this high <em>viral</em> <em>load</em>. Where the person is in the late stages of infection rates of transmission are approximately eight fold greater.","p23":"Infection with HIV-1 is associated with a progressive decrease of the CD4+ T cell count and an increase in <em>viral</em> <em>load</em>, the level of HIV in the blood. The stage of infection can be determined by measuring the persons's CD4+ T cell count and <em>viral</em> <em>load</em>.","p24":"A small percentage of HIV-1 infected individuals retain high levels of CD4+ T-cells without antiretroviral therapy. However, most have detectable <em>viral</em> <em>load</em> and will eventually progress to AIDS without treatment. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and also have low or clinically undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as elite controllers or elite suppressors (ES).","p25":"","p26":"","p27":""},{"revision_id":892,"revision_timestamp":"2012-06-07T04:40:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":891,"revision_timestamp":"2012-06-07T04:41:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"When to start HART is still subject to debate. In the developed world when to start treatment is based on the <em>viral</em> <em>load</em>, how fast CD4 declines, and patient readiness. The United States Panel on Antiretroviral Guidelines in 2009 recommended that antiretroviral therapy should be initiated in all people with a CD4 count less than 350, with treatment also recommended with CD4 counts between 350 and 500.","p26":"","p27":""},{"revision_id":890,"revision_timestamp":"2012-06-07T04:49:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"When to start HART is still subject to debate. In the developed world when to start treatment is based on the <em>viral</em> <em>load</em>, how fast CD4 declines, and patient readiness. The United States Panel on Antiretroviral Guidelines in 2009 recommended that antiretroviral therapy should be initiated in all people with a CD4 count less than 350, with treatment also recommended with CD4 counts between 350 and 500.","p26":"","p27":""},{"revision_id":889,"revision_timestamp":"2012-06-07T04:53:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"When to start HART is still subject to debate. In the developed world when to start treatment is based on the <em>viral</em> <em>load</em>, how fast CD4 declines, and patient readiness. The United States Panel on Antiretroviral Guidelines in 2009 recommended that antiretroviral therapy should be initiated in all people with a CD4 count less than 350, with treatment also recommended with CD4 counts between 350 and 500. However, those with CD4 counts over 500, the expert panel was evenly divided, with half in favor of starting antiretroviral therapy at this stage, and half viewing initiating therapy as optional.","p26":"","p27":""},{"revision_id":883,"revision_timestamp":"2012-06-07T21:17:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"When to start HART is still subject to debate. In the developed world when to start treatment is based on the <em>viral</em> <em>load</em>, how fast CD4 declines, and patient readiness. The United States Panel on Antiretroviral Guidelines in 2009 recommended that antiretroviral therapy should be initiated in all people with a CD4 count less than 350, with treatment also recommended with CD4 counts between 350 and 500. However, those with CD4 counts over 500, the expert panel was evenly divided, with half in favor of starting antiretroviral therapy at this stage, and half viewing initiating therapy as optional.","p26":"","p27":""},{"revision_id":882,"revision_timestamp":"2012-06-07T21:20:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":849,"revision_timestamp":"2012-06-08T06:37:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"A strong immune defense reduces the number of viral particles in the blood stream, marking the start of secondary or chronic HIV infection. The secondary stage of HIV infection can vary between two weeks and 20 years. During this phase of infection, HIV is active within lymph nodes, which typically become persistently swollen, in response to large amounts of virus that become trapped in the follicular dendritic cells (FDC) network. The surrounding tissues that are rich in CD4+ T cells may also become infected, and viral particles accumulate both in infected cells and as free virus. Individuals who are in this phase are still infectious. During this time, CD4+ CD45RO+ T cells carry most of the pro<em>viral</em> <em>load</em>.","p27":""},{"revision_id":844,"revision_timestamp":"2012-06-08T08:11:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":"In developing countries, the World Health Organization's staging system for HIV infection and disease is used (using clinical and laboratory data), and in developed countries the CDC's classification system is used. The stage of infection is typically determined by measuring the persons's CD4+ T cell count and <em>viral</em> <em>load</em>."},{"revision_id":842,"revision_timestamp":"2012-06-08T08:49:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"A small percentage of HIV-1 infected individuals retain high levels of CD4+ T-cells without antiretroviral therapy. However, most have detectable <em>viral</em> <em>load</em> and will eventually progress to AIDS without treatment. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and also have low or clinically undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as elite controllers or elite suppressors (ES).","p25":"","p26":"","p27":"In developing countries, the World Health Organization's staging system for HIV infection and disease is used (using clinical and laboratory data), and in developed countries the CDC's classification system is used. The stage of infection is typically determined by measuring the persons's CD4+ T cell count and <em>viral</em> <em>load</em>."},{"revision_id":773,"revision_timestamp":"2012-06-11T08:25:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelvefold higher due to this high <em>viral</em> <em>load</em>. Where the person is in the late stages of infection rates of transmission are approximately eightfold greater.","p23":"","p24":"A small percentage (~5%) of HIV-1 infected individuals retain high levels of CD4+ T-cells without antiretroviral therapy for more than 5 years. However, most have detectable <em>viral</em> <em>load</em> and will eventually progress to AIDS without treatment. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and also have low or clinically undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as elite controllers or elite suppressors.","p25":"","p26":"","p27":""},{"revision_id":729,"revision_timestamp":"2012-06-14T10:42:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelvefold higher due to this high <em>viral</em> <em>load</em>. Where the person is in the late stages of infection rates of transmission are approximately eightfold greater.","p23":"","p24":"A small percentage (~5%) of HIV-1 infected individuals retain high levels of CD4+ T-cells without antiretroviral therapy for more than 5 years. However, most have detectable <em>viral</em> <em>load</em> and will eventually progress to AIDS without treatment. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and also have low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as elite controllers or elite suppressors.","p25":"","p26":"","p27":""},{"revision_id":716,"revision_timestamp":"2012-06-15T10:20:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelvefold higher due to this high <em>viral</em> <em>load</em>. Where the person is in the late stages of infection rates of transmission are approximately eightfold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":715,"revision_timestamp":"2012-06-16T17:07:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":676,"revision_timestamp":"2012-06-25T19:04:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelvefold higher due to this high <em>viral</em> <em>load</em>. Where the person is in the late stages of infection rates of transmission are approximately eightfold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":673,"revision_timestamp":"2012-06-25T23:00:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 month of an HIV infection a persons infectiousness is twelvefold higher due to this high <em>viral</em> <em>load</em>. Where the person is in the late stages of infection rates of transmission are approximately eightfold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":625,"revision_timestamp":"2012-07-29T18:42:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":603,"revision_timestamp":"2012-08-06T13:15:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 months of an HIV infection a person's infectiousness is twelve times higher due to this high <em>viral</em> <em>load</em>. Where the person is in the late stages of infection rates of transmission are approximately eightfold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":588,"revision_timestamp":"2012-08-09T02:30:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"A small percentage (~5%) of HIV-1 infected individuals retain high levels of CD4+ T-cells without antiretroviral therapy for more than 5 years. However, most have detectable <em>viral</em> <em>load</em> and will eventually progress to AIDS without treatment. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and also have low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as elite controllers or elite suppressors.","p25":"","p26":"","p27":""},{"revision_id":581,"revision_timestamp":"2012-08-09T12:09:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and without treatment will eventually progress to AIDS, a small proportion (~5%) retain high levels of CD4+ T-cells without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and also have low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as elite controllers or elite suppressors.","p25":"","p26":"","p27":""},{"revision_id":580,"revision_timestamp":"2012-08-09T12:20:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (~5%) retain high levels of CD4+ T-cells without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and also have low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as elite controllers or elite suppressors.","p25":"","p26":"","p27":""},{"revision_id":578,"revision_timestamp":"2012-08-09T12:34:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (~5%) retain high levels of CD4+ T-cells without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP), and those who also maintain a low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as \"elite controllers\" or \"elite suppressors\".","p25":"","p26":"","p27":""},{"revision_id":575,"revision_timestamp":"2012-08-11T10:35:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is important both in heterosexual and vertical transmission. During the first 2.5 months of an HIV infection a person's infectiousness is twelve times higher due to this high <em>viral</em> <em>load</em>. If the person is in the late stages of infection, rates of transmission are approximately eightfold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":565,"revision_timestamp":"2012-08-13T07:18:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (~5%) retain high levels of CD4+ T-cells without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP), and those who also maintain a low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as \"elite controllers\" or \"elite suppressors\".","p25":"","p26":"","p27":""},{"revision_id":564,"revision_timestamp":"2012-08-13T07:20:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (~5%) retain high levels of CD4+ T-cells without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP), and those who also maintain a low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as \"elite controllers\" or \"elite suppressors\".","p25":"","p26":"","p27":""},{"revision_id":563,"revision_timestamp":"2012-08-13T13:50:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (~5%) retain high levels of CD4+ T cells (T helper cells) without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP), and those who also maintain a low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as \"elite controllers\" or \"elite suppressors\".","p25":"","p26":"","p27":""},{"revision_id":555,"revision_timestamp":"2012-08-14T09:38:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is an important risk factor both in heterosexual and vertical transmission. During the first 2.5 months of an HIV infection a person's infectiousness is twelve times higher due to this high <em>viral</em> <em>load</em>. If the person is in the late stages of infection, rates of transmission are approximately eightfold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":552,"revision_timestamp":"2012-08-14T09:53:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is an important risk factor both in sexual as well as mother-to-child transmission. During the first 2.5 months of an HIV infection a person's infectiousness is twelve times higher due to this high <em>viral</em> <em>load</em>. If the person is in the late stages of infection, rates of transmission are approximately eightfold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":522,"revision_timestamp":"2012-08-14T19:23:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is an important risk factor in sexual as well as mother-to-child transmission. During the first 2.5 months of an HIV infection a person's infectiousness is twelve times higher due to this high <em>viral</em> <em>load</em>. If the person is in the late stages of infection, rates of transmission are approximately eightfold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":483,"revision_timestamp":"2012-08-16T09:34:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (~5%) retain high levels of CD4+ T cells (T helper cells) without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP), and those who also maintain a low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as \"elite controllers\" or \"elite suppressors\".","p25":"","p26":"","p27":""},{"revision_id":435,"revision_timestamp":"2012-09-17T19:34:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (about 5%) retain high levels of CD4+ T cells (T helper cells) without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP), and those who also maintain a low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment are known as \"elite controllers\" or \"elite suppressors\".","p25":"","p26":"","p27":""},{"revision_id":374,"revision_timestamp":"2013-03-03T22:31:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (about 5%) retain high levels of CD4+ T cells (T helper cells) without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). Another group is those who also maintain a low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment who are known as \"elite controllers\" or \"elite suppressors\". They represent approximately 1 in 300 infected persons.","p25":"","p26":"","p27":""},{"revision_id":312,"revision_timestamp":"2013-03-27T15:16:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":297,"revision_timestamp":"2013-04-16T12:42:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is an important risk factor in both sexual and mother-to-child transmission. During the first 2.5 months of an HIV infection a person's infectiousness is twelve times higher due to this high <em>viral</em> <em>load</em>. If the person is in the late stages of infection, rates of transmission are approximately eightfold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":223,"revision_timestamp":"2013-08-18T03:05:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":197,"revision_timestamp":"2013-10-12T23:24:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":175,"revision_timestamp":"2013-11-26T02:37:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":163,"revision_timestamp":"2013-12-24T18:43:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"The <em>viral</em> <em>load</em> of an infected person is an important risk factor in both sexual and mother-to-child transmission. During the first 2.5 months of an HIV infection a person's infectiousness is twelve times higher due to this high <em>viral</em> <em>load</em>. If the person is in the late stages of infection, rates of transmission are approximately eightfold greater.","p23":"","p24":"","p25":"","p26":"","p27":""},{"revision_id":102,"revision_timestamp":"2014-04-16T07:45:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (about 5%) retain high levels of CD4+ T cells (T helper cells) without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). Another group is those who also maintain a low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment who are known as \"elite controllers\" or \"elite suppressors\". They represent approximately 1 in 300 infected persons.","p25":"","p26":"","p27":""},{"revision_id":87,"revision_timestamp":"2014-05-28T02:44:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (about 5%) retain high levels of CD4 T cells (T helper cells) without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). Another group is those who also maintain a low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment who are known as \"elite controllers\" or \"elite suppressors\". They represent approximately 1 in 300 infected persons.","p25":"","p26":"","p27":""},{"revision_id":77,"revision_timestamp":"2014-05-31T18:39:00.000Z","p1":"","p2":"","p3":"","p4":"","p5":"","p6":"","p7":"","p8":"","p9":"","p10":"","p11":"","p12":"","p13":"","p14":"","p15":"","p16":"","p17":"","p18":"","p19":"","p20":"","p21":"","p22":"","p23":"","p24":"Although most HIV-1 infected individuals have a detectable <em>viral</em> <em>load</em> and in the absence of treatment will eventually progress to AIDS, a small proportion (about 5%) retain high levels of CD4+ T cells (T helper cells) without antiretroviral therapy for more than 5 years. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). Another group is those who also maintain a low or undetectable <em>viral</em> <em>load</em> without anti-retroviral treatment who are known as \"elite controllers\" or \"elite suppressors\". They represent approximately 1 in 300 infected persons.","p25":"","p26":""}]